Literature DB >> 30763715

Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells.

Bethtrice Elliott1, Ana Cecilia Millena1, Lilya Matyunina2, Mengnan Zhang2, Jin Zou1, Guangdi Wang3, Qiang Zhang3, Nathan Bowen1, Vanessa Eaton1, Gabrielle Webb1, Shadyra Thompson1, John McDonald2, Shafiq Khan4.   

Abstract

JunD, a member of the AP-1 family, is essential for cell proliferation in prostate cancer (PCa) cells. We recently demonstrated that JunD knock-down (KD) in PCa cells results in cell cycle arrest in G1-phase concomitant with a decrease in cyclin D1, Ki67, and c-MYC, but an increase in p21 levels. Furthermore, the over-expression of JunD significantly increased proliferation suggesting JunD regulation of genes required for cell cycle progression. Here, employing gene expression profiling, quantitative proteomics, and validation approaches, we demonstrate that JunD KD is associated with distinct gene and protein expression patterns. Comparative integrative analysis by Ingenuity Pathway Analysis (IPA) identified 1) cell cycle control/regulation as the top canonical pathway whose members exhibited a significant decrease in their expression following JunD KD including PRDX3, PEA15, KIF2C, and CDK2, and 2) JunD dependent genes are associated with cell proliferation, with MYC as the critical downstream regulator. Conversely, JunD over-expression induced the expression of the above genes including c-MYC. We conclude that JunD is a crucial regulator of cell cycle progression and inhibiting its target genes may be an effective approach to block prostate carcinogenesis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer initiation; Cell cycle regulation; JunD; Prostate cancer; c-MYC

Mesh:

Substances:

Year:  2019        PMID: 30763715      PMCID: PMC6414252          DOI: 10.1016/j.canlet.2019.02.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  88 in total

Review 1.  Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance.

Authors:  Rodolfo Montironi; Roberta Mazzucchelli; Antonio Lopez-Beltran; Marina Scarpelli; Liang Cheng
Journal:  BJU Int       Date:  2011-08-26       Impact factor: 5.588

2.  JunD-mediated repression of GADD45α and γ regulates escape from cell death in prostate cancer.

Authors:  Luiz Fernando Zerbini; Jaíra Ferreira de Vasconcellos; Akos Czibere; Yihong Wang; Juliano D Paccez; Xuesong Gu; Jin-Rong Zhou; Towia A Libermann
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

Review 3.  The role of GATA2 in lethal prostate cancer aggressiveness.

Authors:  Veronica Rodriguez-Bravo; Marc Carceles-Cordon; Yujin Hoshida; Carlos Cordon-Cardo; Matthew D Galsky; Josep Domingo-Domenech
Journal:  Nat Rev Urol       Date:  2016-11-22       Impact factor: 14.432

4.  Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.

Authors:  Karin Williams; Suzanne Fernandez; Xavier Stien; Kenichiro Ishii; Harold D Love; Yun-Fai Chris Lau; Richard L Roberts; Simon W Hayward
Journal:  Prostate       Date:  2005-06-01       Impact factor: 4.104

5.  Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration.

Authors:  BaoHan T Vo; Shafiq A Khan
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

6.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process.

Authors:  Uma R Chandran; Changqing Ma; Rajiv Dhir; Michelle Bisceglia; Maureen Lyons-Weiler; Wenjing Liang; George Michalopoulos; Michael Becich; Federico A Monzon
Journal:  BMC Cancer       Date:  2007-04-12       Impact factor: 4.430

7.  c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.

Authors:  M K Mateyak; A J Obaya; J M Sedivy
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

8.  The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc.

Authors:  John R Prensner; Wei Chen; Sumin Han; Matthew K Iyer; Qi Cao; Vishal Kothari; Joseph R Evans; Karen E Knudsen; Michelle T Paulsen; Mats Ljungman; Theodore S Lawrence; Arul M Chinnaiyan; Felix Y Feng
Journal:  Neoplasia       Date:  2014-11-20       Impact factor: 5.715

9.  Expression, Clinical Significance, and Functional Prediction of MNX1 in Breast Cancer.

Authors:  Tian Tian; Meng Wang; Yuyao Zhu; Wenge Zhu; Tielin Yang; Hongtao Li; Shuai Lin; Cong Dai; Yujiao Deng; Dingli Song; Na Li; Zhen Zhai; Zhi-Jun Dai
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-27       Impact factor: 8.886

10.  Heat Shock Protein 90α-Dependent B-Cell-2-Associated Transcription Factor 1 Promotes Hepatocellular Carcinoma Proliferation by Regulating MYC Proto-Oncogene c-MYC mRNA Stability.

Authors:  Xueqiong Zhou; Ying Wen; Ye Tian; Meiling He; Xiangyu Ke; Zhizhou Huang; Yangfan He; Lixia Liu; Annette Scharf; Meiting Lu; Guowei Zhang; Yaotang Deng; Yuxia Yan; Matthias P Mayer; Xuemei Chen; Fei Zou
Journal:  Hepatology       Date:  2018-10-04       Impact factor: 17.425

View more
  16 in total

1.  MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin.

Authors:  Yakun Luo; Virginie Vlaeminck-Guillem; Silvère Baron; Sarah Dallel; Chang Xian Zhang; Muriel Le Romancer
Journal:  J Exp Clin Cancer Res       Date:  2021-08-26

2.  Diseasome and comorbidities complexities of SARS-CoV-2 infection with common malignant diseases.

Authors:  Md Shahriare Satu; Md Imran Khan; Md Rezanur Rahman; Koushik Chandra Howlader; Shatabdi Roy; Shuvo Saha Roy; Julian M W Quinn; Mohammad Ali Moni
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 11.622

Review 3.  Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression.

Authors:  Tayaba Ismail; Youni Kim; Hongchan Lee; Dong-Seok Lee; Hyun-Shik Lee
Journal:  Int J Mol Sci       Date:  2019-09-07       Impact factor: 5.923

4.  LncRNA SNHG7 Functions as an Oncogene in Cervical Cancer by Sponging miR-485-5p to Modulate JUND Expression.

Authors:  Danyang Zhao; Hui Zhang; Jianxiong Long; Mujun Li
Journal:  Onco Targets Ther       Date:  2020-02-25       Impact factor: 4.147

5.  Inhibition of breast cancer growth via miR-7 suppressing ALDH1A3 activity concomitant with decreasing breast cancer stem cell subpopulation.

Authors:  Meng Pan; Miao Li; Chengzhong You; Fengshu Zhao; Mei Guo; Hui Xu; Luoyang Li; Ling Wang; Jun Dou
Journal:  J Cell Physiol       Date:  2019-07-25       Impact factor: 6.384

6.  Fargesin Inhibits EGF-Induced Cell Transformation and Colon Cancer Cell Growth by Suppression of CDK2/Cyclin E Signaling Pathway.

Authors:  Ga-Eun Lee; Cheol-Jung Lee; Hyun-Jung An; Han Chang Kang; Hye Suk Lee; Joo Young Lee; Sei-Ryang Oh; Sung-Jun Cho; Dae Joon Kim; Yong-Yeon Cho
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

7.  A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb target genes.

Authors:  Yueyuan Zheng; Guowei Huang; Tiago C Silva; Qian Yang; Yan-Yi Jiang; H Phillip Koeffler; De-Chen Lin; Benjamin P Berman
Journal:  Nat Commun       Date:  2021-04-30       Impact factor: 14.919

8.  PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer.

Authors:  Xin Jin; Rui Fang; Ping Fan; Lipeng Zeng; Bin Zhang; Xiaoming Lu; Tao Liu
Journal:  J Exp Clin Cancer Res       Date:  2019-11-12

Review 9.  Selective antagonism of cJun for cancer therapy.

Authors:  Andrew Brennan; James T Leech; Neil M Kad; Jody M Mason
Journal:  J Exp Clin Cancer Res       Date:  2020-09-11

10.  Prognostic Signature of Osteosarcoma Based on 14 Autophagy-Related Genes.

Authors:  Wei Qi; Qian Yan; Ming Lv; Delei Song; Xianbin Wang; Kangsong Tian
Journal:  Pathol Oncol Res       Date:  2021-07-16       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.